Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations

4 Apr 2013

Abstract excerpt

The evolution of drug resistance in fungal pathogens compromises the efficacy of the limited number of antifungal drugs. Drug combinations have emerged as a powerful strategy to enhance antifungal efficacy and abrogate drug resistance, but the impact on the evolution of drug resistance remains largely unexplored. Targeting the molecular chaperone Hsp90 or its downstream effector, the protein phosphatase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Helminth infection and control
Share to Microbial Natural Products and Biosynthesis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23593013
DOI: 10.1371/journal.pgen.1003390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug CombinationsPMID 23593013Read ↗

Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug CombinationsSemantic proximity Read ↗

Genetic architecture of Hsp90-dependent drug resistance.Semantic proximity Read ↗

Metabolic control of antifungal drug resistance.Semantic proximity Read ↗

Most azole antifungal resistance mutations in the drug target provide cross-resistance and carry no intrinsic fitness costSemantic proximity Read ↗

Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost.Semantic proximity Read ↗

Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs.Semantic proximity Read ↗

Identification and characterization of non-canonical azole antifungal resistance pathways in Aspergillus fumigatus.Semantic proximity Read ↗

The evolution of drug resistance in clinical isolates of Candida albicans.Semantic proximity Read ↗

Fitness trade-offs restrict the evolution of resistance to amphotericin B.Semantic proximity Read ↗

The Microevolution of Antifungal Drug Resistance in Pathogenic FungiSemantic proximity Read ↗

Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance.Semantic proximity Read ↗

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida SpeciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.